Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies
on the Outcome of First-Line Therapy in Metastatic Colorectal
Cancer Patients: a Retrospective Registry-Based Analysis

J 2018

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

FIALA, Ondrej, Veronika VESKRNOVA, Renata CHLOUPKOVÁ, Alexandr POPRACH, Igor KISS et. al.

Basic information

Original name

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

Authors

FIALA, Ondrej (203 Czech Republic), Veronika VESKRNOVA (203 Czech Republic), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Katerina KOPECKOVA (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Lubomir SLAVICEK (203 Czech Republic), Milan KOHOUTEK (203 Czech Republic), Jindrich FINEK, Marek SVOBODA (203 Czech Republic, belonging to the institution), Lubos PETRUZELKA (203 Czech Republic), Ludmila BOUBLIKOVA (203 Czech Republic), Josef DVORAK (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic) and Tomas BUCHLER (203 Czech Republic, guarantor)

Edition

Targeted Oncology, Dordrecht, Springer, 2018, 1776-2596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.683

RIV identification code

RIV/00216224:14110/18:00105155

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s11523-018-0597-7

UT WoS

000453659300007

Keywords in English

Anti-EGFR Monoclonal Antibodies; Colorectal Cancer

Abstract

V originále

BackgroundThe addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results.ObjectiveTo determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens.Patients and MethodsClinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n=401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n=71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n=101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle.ResultsThree hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9months (95% CI 28.6-47.3) for cohort C, respectively.ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.

Citovat

FIALA, Ondrej, Veronika VESKRNOVA, Renata CHLOUPKOVÁ, Alexandr POPRACH, Igor KISS, Katerina KOPECKOVA, Ladislav DUŠEK, Lubomir SLAVICEK, Milan KOHOUTEK, Jindrich FINEK, Marek SVOBODA, Lubos PETRUZELKA, Ludmila BOUBLIKOVA, Josef DVORAK, Bohuslav MELICHAR and Tomas BUCHLER. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology. Dordrecht: Springer, 2018, vol. 13, No 6, p. 735-743. ISSN 1776-2596. Available from: https://dx.doi.org/10.1007/s11523-018-0597-7.

@article{1482502,
   author = {Fiala, Ondrej and Veskrnova, Veronika and Chloupková, Renata and Poprach, Alexandr and Kiss, Igor and Kopeckova, Katerina and Dušek, Ladislav and Slavicek, Lubomir and Kohoutek, Milan and Finek, Jindrich and Svoboda, Marek and Petruzelka, Lubos and Boublikova, Ludmila and Dvorak, Josef and Melichar, Bohuslav and Buchler, Tomas},
   article_location = {Dordrecht},
   article_number = {6},
   doi = {http://dx.doi.org/10.1007/s11523-018-0597-7},
   keywords = {Anti-EGFR Monoclonal Antibodies; Colorectal Cancer},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis},
   volume = {13},
   year = {2018}
}

TY  - JOUR
ID  - 1482502
AU  - Fiala, Ondrej - Veskrnova, Veronika - Chloupková, Renata - Poprach, Alexandr - Kiss, Igor - Kopeckova, Katerina - Dušek, Ladislav - Slavicek, Lubomir - Kohoutek, Milan - Finek, Jindrich - Svoboda, Marek - Petruzelka, Lubos - Boublikova, Ludmila - Dvorak, Josef - Melichar, Bohuslav - Buchler, Tomas
PY  - 2018
TI  - Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
JF  - Targeted Oncology
VL  - 13
IS  - 6
SP  - 735-743
EP  - 735-743
PB  - Springer
SN  - 17762596
KW  - Anti-EGFR Monoclonal Antibodies
KW  - Colorectal Cancer
N2  - BackgroundThe addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results.ObjectiveTo determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens.Patients and MethodsClinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n=401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n=71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n=101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle.ResultsThree hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9months (95% CI 28.6-47.3) for cohort C, respectively.ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.
ER  -

FIALA, Ondrej, Veronika VESKRNOVA, Renata CHLOUPKOVÁ, Alexandr POPRACH, Igor KISS, Katerina KOPECKOVA, Ladislav DUŠEK, Lubomir SLAVICEK, Milan KOHOUTEK, Jindrich FINEK, Marek SVOBODA, Lubos PETRUZELKA, Ludmila BOUBLIKOVA, Josef DVORAK, Bohuslav MELICHAR and Tomas BUCHLER. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. \textit{Targeted Oncology}. Dordrecht: Springer, 2018, vol.~13, No~6, p.~735-743. ISSN~1776-2596. Available from: https://dx.doi.org/10.1007/s11523-018-0597-7.

Detailed Information on Publication Record